8-K: Ocugen Licenses OCU400 Gene Therapy to Kwangdong for Korea

Ocugen, Inc. has entered into an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for its OCU400 gene therapy in the Republic of Korea, including an upfront payment, milestones, and royalties.

Summary

• Ocugen, Inc. (Ocugen) signed an Exclusive License Agreement with Kwangdong Pharmaceutical Co., Ltd. (Kwangdong) on September 11, 2025.
• Kwangdong received an exclusive, non-sublicensable, royalty-bearing license to commercialize OCU400, Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP), in the Republic of Korea.
• Kwangdong will manage all regulatory submissions and communications in the Territory and is committed to using commercially reasonable efforts to develop and obtain regulatory approval for OCU400.
• Ocugen will receive an upfront license fee of $1 million.
• Ocugen is eligible for up to $6.5 million upon achieving certain regulatory and development milestones.
• Ocugen will also receive $1.5 million for every $15 million of sales in the Territory, upon achievement of certain sales milestones.
• Ocugen will receive a royalty of 25% on net sales of OCU400 generated by Kwangdong.
• Ocugen will be responsible for manufacturing the commercial supply of OCU400 under a separate supply agreement.
• The agreement's term extends until the last of: 20 years from the first commercial sale, expiration of the last valid patent claim, or expiration of exclusive marketing/data exclusivity rights in the Territory.

Sentiment

Score: 8

Explanation: The exclusive license agreement is a strong positive development. It provides non-dilutive funding through upfront and milestone payments, establishes a significant royalty stream, and expands the market for a key gene therapy asset (OCU400) into a new territory without direct commercialization costs for Ocugen in that region. This validates the asset and de-risks its global development.

Positives

• Secured an upfront payment of $1 million, providing immediate non-dilutive capital.
• Potential to receive up to $6.5 million in regulatory and development milestones, validating the OCU400 asset and supporting its progression.
• Established a long-term revenue stream through a 25% royalty on net sales and additional sales milestones ($1.5 million for every $15 million in sales).
• Expanded market reach for OCU400 into the Republic of Korea without direct commercialization costs for Ocugen in that territory.
• Kwangdong will bear the responsibility and costs for regulatory submissions and development efforts in the Republic of Korea.
• Ocugen retains ownership of the global safety database for OCU400.

Risks

• The license agreement with Kwangdong may not lead to the anticipated benefits for Ocugen.
• Preliminary, interim, and top-line clinical trial results may not be indicative of, and may differ from, final clinical data.
• OCU400 may not perform in humans in a manner consistent with nonclinical or preclinical study data.
• Unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data.
• Earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.

Future Outlook

Ocugen anticipates that the license agreement will lead to benefits, including the development and commercialization of OCU400 in the Republic of Korea, generating upfront, milestone, and royalty payments. Kwangdong is expected to use commercially reasonable efforts to develop and seek regulatory approval for OCU400 in the Territory.

Management Comments

• Ocugen's Chairman, Chief Executive Officer, & Co-Founder, Shankar Musunuri, signed the exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. on behalf of the company.

Industry Context

This agreement highlights the growing trend of biotechnology companies leveraging licensing deals to expand the global reach of novel gene therapies, particularly for rare diseases like retinitis pigmentosa. Such partnerships allow companies to access new markets and share development risks, while local partners benefit from innovative treatments.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the agreement's terms against global benchmarks for similar gene therapy licensing deals.

Stakeholder Impact

• Shareholders: Potential for increased revenue through upfront payments, milestones, and royalties, which could positively impact stock valuation.
• Patients (Republic of Korea): Potential future access to a novel gene therapy (OCU400) for retinitis pigmentosa.
• Employees: Continued focus on manufacturing and global safety database management for OCU400.

Next Steps

• Kwangdong Pharmaceutical Co., Ltd. will proceed with preparing, filing, and maintaining regulatory submissions for OCU400 in the Republic of Korea.
• Kwangdong will use commercially reasonable efforts to develop, seek, register, and obtain regulatory approval for OCU400 in the Territory.
• Ocugen will manufacture the commercial supply of OCU400 under a supply agreement.
• Ocugen will file a copy of the Agreement as an exhibit in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Key Dates

Recommendation

The exclusive license agreement for OCU400 in the Republic of Korea represents a positive strategic move, providing Ocugen with an upfront payment, significant potential milestone payments, and a 25% royalty on net sales. This deal validates the OCU400 asset, expands its market reach into a new territory, and provides a non-dilutive revenue stream, which is beneficial for a biotechnology company developing novel therapies. While the upfront payment is modest, the potential for future payments and royalties offers substantial upside, making this a favorable development for investors.

Keywords

Ocugen, Kwangdong Pharmaceutical, OCU400, Gene Therapy, Retinitis Pigmentosa, RP, Exclusive License Agreement, South Korea, Biotechnology, Pharmaceutical, Rare Disease